Broad Protection Against Clade 1 Sarbecoviruses After a Single Immunization with Cocktail Spike-protein-nanoparticle Vaccine

Overview

Journal Nat Commun

Specialty Biology

Date 2024 Feb 12

PMID 38346966

Authors

Peter J Halfmann

Kathryn Loeffler

Augustine Duffy

Makoto Kuroda

Jie E Yang

Elizabeth R Wright

Yoshihiro Kawaoka

Ravi S Kane

Affiliations

Soon will be listed here.

Abstract

The 2002 SARS outbreak, the 2019 emergence of COVID-19, and the continuing evolution of immune-evading SARS-CoV-2 variants together highlight the need for a broadly protective vaccine against ACE2-utilizing sarbecoviruses. While updated variant-matched formulations are a step in the right direction, protection needs to extend beyond SARS-CoV-2 and its variants to include SARS-like viruses. Here, we introduce bivalent and trivalent vaccine formulations using our spike protein nanoparticle platform that completely protect female hamsters against BA.5 and XBB.1 challenges with no detectable virus in the lungs. The trivalent cocktails elicit highly neutralizing responses against all tested Omicron variants and the bat sarbecoviruses SHC014 and WIV1. Finally, our 614D/SHC014/XBB trivalent spike formulation completely protects human ACE2-transgenic female hamsters against challenges with WIV1 and SHC014 with no detectable virus in the lungs. Collectively, these results illustrate that our trivalent protein-nanoparticle cocktail can provide broad protection against SARS-CoV-2-like and SARS-CoV-1-like sarbecoviruses.

Citing Articles

Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice.

Halfmann P, Patel R, Loeffler K, Yasuhara A, Van de Velde L, Yang J Nat Commun. 2025; 16(1):462.

PMID: 39774966 PMC: 11706982. DOI: 10.1038/s41467-025-55824-y.

Single immunization with an influenza hemagglutinin nanoparticle-based vaccine elicits durable protective immunity.

Chiba S, Maemura T, Loeffler K, Frey S, Gu C, Biswas A Bioeng Transl Med. 2024; 9(5):e10689.

PMID: 39553436 PMC: 11561850. DOI: 10.1002/btm2.10689.

Distinct pathways for evolution of enhanced receptor binding and cell entry in SARS-like bat coronaviruses.

Tse A, Acreman C, Ricardo-Lax I, Berrigan J, Lasso G, Balogun T PLoS Pathog. 2024; 20(11):e1012704.

PMID: 39546542 PMC: 11602109. DOI: 10.1371/journal.ppat.1012704.

References

Chi W, Li Y, Huang H, Chan T, Chow S, Su J . COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci. 2022; 29(1):82. PMC: 9569411. DOI: 10.1186/s12929-022-00853-8. View

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Dunkle L, Kotloff K, Gay C, Anez G, Adelglass J, Barrat Hernandez A . Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med. 2021; 386(6):531-543. PMC: 8693692. DOI: 10.1056/NEJMoa2116185. View

Huang Y, Yang C, Xu X, Xu W, Liu S . Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020; 41(9):1141-1149. PMC: 7396720. DOI: 10.1038/s41401-020-0485-4. View

Khoury D, Cromer D, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(7):1205-1211. DOI: 10.1038/s41591-021-01377-8. View

Temmam S, Vongphayloth K, Baquero E, Munier S, Bonomi M, Regnault B . Bat coronaviruses related to SARS-CoV-2 and infectious for human cells. Nature. 2022; 604(7905):330-336. DOI: 10.1038/s41586-022-04532-4. View

Ng K, Faulkner N, Finsterbusch K, Wu M, Harvey R, Hussain S . SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies. Sci Transl Med. 2022; 14(655):eabn3715. DOI: 10.1126/scitranslmed.abn3715. View

10.

Link-Gelles R, Ciesla A, Fleming-Dutra K, Smith Z, Britton A, Wiegand R . Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(48):1526-1530. PMC: 9721148. DOI: 10.15585/mmwr.mm7148e1. View

11.

Hoffmann M, Behrens G, Arora P, Kempf A, Nehlmeier I, Cossmann A . Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation. Lancet Infect Dis. 2022; 23(1):25-28. PMC: 9721839. DOI: 10.1016/S1473-3099(22)00792-7. View

12.

Davis-Gardner M, Lai L, Wali B, Samaha H, Solis D, Lee M . Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N Engl J Med. 2022; 388(2):183-185. PMC: 9812288. DOI: 10.1056/NEJMc2214293. View

13.

Tan C, Chia W, Young B, Zhu F, Lim B, Sia W . Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors. N Engl J Med. 2021; 385(15):1401-1406. PMC: 8422514. DOI: 10.1056/NEJMoa2108453. View

14.

Cohen A, Gnanapragasam P, Lee Y, Hoffman P, Ou S, Kakutani L . Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science. 2021; 371(6530):735-741. PMC: 7928838. DOI: 10.1126/science.abf6840. View

15.

Cohen A, van Doremalen N, Greaney A, Andersen H, Sharma A, Starr T . Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science. 2022; 377(6606):eabq0839. PMC: 9273039. DOI: 10.1126/science.abq0839. View

16.

Du P, Li N, Xiong X, Tang S, Dai Q, Liu Z . A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity. J Med Virol. 2022; 94(9):4287-4293. DOI: 10.1002/jmv.27885. View

17.

Brinkkemper M, Veth T, Brouwer P, Turner H, Poniman M, Burger J . Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses. iScience. 2022; 25(12):105649. PMC: 9678814. DOI: 10.1016/j.isci.2022.105649. View

18.

Brouwer P, Brinkkemper M, Maisonnasse P, Dereuddre-Bosquet N, Grobben M, Claireaux M . Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell. 2021; 184(5):1188-1200.e19. PMC: 7834972. DOI: 10.1016/j.cell.2021.01.035. View

19.

Joyce M, King H, Elakhal-Naouar I, Ahmed A, Peachman K, Cincotta C . A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. Sci Transl Med. 2021; 14(632):eabi5735. DOI: 10.1126/scitranslmed.abi5735. View

20.

Weidenbacher P, Sanyal M, Friedland N, Tang S, Arunachalam P, Hu M . A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. Nat Commun. 2023; 14(1):2149. PMC: 10110616. DOI: 10.1038/s41467-023-37417-9. View